ArticleClinical investigation2014
Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.
Article in Clinical investigation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- The feasibility of [Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Cancer stem cell plasticity in shaping drug resistance landscapes in prostate cancer.Journal of advanced research · 2026Review
- Phytochemical Profiling of the Halophyte Artemisia fukudo Makino and Its In Vitro Effects on Androgen-Related Pathways Associated With Benign Prostatic Hyperplasia and Alopecia.ChemistryOpen · 2026Article
- Association between dietary calcium intake and benign prostatic hyperplasia: a population-based result from NHANES 2003 to 2008.Translational andrology and urology · 2025Article
- Advances in the identification of novel cell signatures in benign prostatic hyperplasia and prostate cancer using single-cell RNA sequencing.Frontiers in immunology · 2025Review
- Rate of castration-induced prostate stroma regression is reduced in a mouse model of benign prostatic hyperplasia.American journal of clinical and experimental urology · 2023Article
- Article
- Prostate luminal progenitor cells: from mouse to human, from health to disease.Nature reviews. Urology · 2022Review
- A Role of the Heme Degradation Pathway in Shaping Prostate Inflammatory Responses and Lipid Metabolism.The American journal of pathology · 2020Article
- Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio.World journal of urology · 2019Article
- Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells.Journal of clinical medicine · 2019Review
- C-C motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment.Cancer science · 2018Article
- Magnetic Resonance Imaging and Molecular Characterization of a Hormone-Mediated Murine Model of Prostate Enlargement and Bladder Outlet Obstruction.The American journal of pathology · 2017Article
- Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 axis.Oncotarget · 2017Article
- N-Butanol and Aqueous Fractions of Red Maca Methanolic Extract Exerts Opposite Effects on Androgen and Oestrogens Receptors (Alpha and Beta) in Rats with Testosterone-Induced Benign Prostatic Hyperplasia.Evidence-based complementary and alternative medicine : eCAM · 2017Article
- Impact of oral capsule ofJournal of renal injury prevention · 2017Article
- Musulju improves benign prostatic hyperplasia by regulating inflammatory and apoptotic proteins.Molecular medicine reports · 2016Article
- Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Both benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are frequent diseases in middle-aged to elderly men worldwide. While both diseases are linked to abnormal growth of the prostate, the epidemiological and pathological features of these two prostate diseases are different. BPH nodules typically arise from the transitional zone, and, in contrast, PCa arises from the peripheral zone. Androgen deprivation therapy alone may not be sufficient to cure these two prostatic diseases due to its undesirable side effects. The alteration of androgen receptor-mediated inflammatory signals from infiltrating immune cells and prostate stromal/epithelial cells may play key roles in those unwanted events. Herein, this review will focus on the roles of androgen/androgen receptor signals in the inflammation-induced progression of BPH and PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.